information
Whoever comes in this website may find a hint
Phage therapy is influenced by:
Phage therapy is influenced by:
Country : the epidemiological situation is different from country to country in terms of circulating bacteria and bacteriophages. Example: a lytic phages from Italy may be no active on the same bacteria (genus and species) isolated from another country and vice versa.
Chronolability
Mutation rate
Phenotypical delay
Phage cocktail
My point of view
Country : the epidemiological situation is different from country to country in terms of circulating bacteria and bacteriophages. Example: a lytic phages from Italy may be no active on the same bacteria (genus and species) isolated from another country and vice versa.
Chronolability
Mutation rate
Phenotypical delay
Phage cocktail
My point of view
From Wikipedia
If the target host* of a phage therapy treatment is not an animal the term "biocontrol" (as in phage-mediated biocontrol of bacteria) is usually employed, rather than "phage therapy".
"In silico"
From:"Genomics,Proteomics and Clinical Bacteriology", N.Woodford and Alan P.Johnson
Phrase that emphasizes the fact that many molecular biologists spend increasing amounts of their time in front of a computer screen, generating hypotheses that can subsequently be tested and (hopefully) confirmed in the laboratory.
Thursday, 30 October 2014
Wednesday, 29 October 2014
Now we all write about Phage therapy but where are the results?
The main target where there is a good chance of success for phage therapy is the skin infection because in this situation there are few adverse factors.
From
The reasons are:
-easy medication
-easy check
- use of one Lytic Phage or Phage cocktail
-direct contact with bacteria
-no antibodies
- easy to remove phage by washing
-et cetera
In my old web site there is this document from :
that now is unobtainable.
Comment:
First we must test phage therapy in this clinical area (and after in the others)
We must consolidate the theory but also to put it into the practice
It is unsatisfactory to write on Phage therapy only for publications
Why the PhagoBurn project is started ? For the same reasons described above .
From
The reasons are:
-easy medication
-easy check
- use of one Lytic Phage or Phage cocktail
-direct contact with bacteria
-no antibodies
- easy to remove phage by washing
-et cetera
In my old web site there is this document from :
that now is unobtainable.
Comment:
First we must test phage therapy in this clinical area (and after in the others)
We must consolidate the theory but also to put it into the practice
It is unsatisfactory to write on Phage therapy only for publications
Why the PhagoBurn project is started ? For the same reasons described above .
Sunday, 26 October 2014
Monday, 20 October 2014
Close study of the poster "Pathogen eradication by phage therapy in patients wich chronic bacterial prostatitis"
Unfortunately for the moment the clinical cases where Phage therapy is applied are infrequent.
For learning it is inevitable to read the experience of others.
I start with a close study of this poster:
1-Disease (here):
2-Methods:
-22 men with CBP and positive bacterial culture of expressed prostatic fluid (EPS)
- bacteria:
E.fecalis: n=16
E.coli: n=5
K.pneumoniae: n=2
P.aeruginosa: n=1
S.haemoliticus: n=1
-No presence of other micro-organisms (Chlamidia, Mycoplasma etc.)*
-No any drugs for at least one month
-measurement of the prostate size and of the urinary flow rate
- measurement of the index NIH-CPSI
-statistical valuation
3-Phage treatment (year 2013):
Comment:
Phage preparation is the same from:
here ( year 1981)
Phage preparation is the same from:
here ( year 2000)
Phage preparation:
4-Results:
Mean PT duration: 47 days
Eradication in 50% of the cases
No side effects
almost too easy!!
Saturday, 18 October 2014
IT 5210045 :Fiume Vigi ,a Special Area of Conservation (SAC) inside of the Sellano territory
Now is a Special Area of Conservation by a law.
Some animals in this area:
From Wikipedia:
"A Special Area of Conservation (SAC) is defined in the European Union's Habitats Directive (92/43/EEC), also known as the Directive on the Conservation of Natural Habitats and of Wild Fauna and Flora. They are to protect the 220 habitats and approximately 1000 species listed in annex I and II of the directive which are considered to be of European interest following criteria given in the directive. They must be chosen from the Sites of Community Importance by the State Members and designated SAC by an act assuring the conservation measures of the natural habitat.
SACs complement Special Protection Areas and together form a network of protected sites across the European Union called Natura 2000. This, in turn, is part of the Emerald network of Areas of Special Conservation Interest (ASCIs) under the Berne Convention"
Seventh updated list of sites of Community importance for the Continental biogeographical region:
Fiume Vigi
Thursday, 16 October 2014
One day, doctors might prescribe viruses instead of antibiotics
Here
Here
Current antibiotic-resistant threats in the U.S.
Priority choice for Phage therapy:
ESBLs :Extended spectrum beta-lactamase -producing Enterobacteriaceae
MRSA:Methicillin-resistant Staphylococcus aureus
VRSA:Vancomycin Resistant Staphylococcus aureus
Friday, 3 October 2014
Subscribe to:
Posts (Atom)